Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Akero Therapeutics Inc 601 GATEWAY BOULEVARD SUITE 350 SOUTH SAN FRANCISCO CA 94080 USA

www.akerotx.com Employees: 56 P: 650-487-6488

Description:

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.

Key Statistics

Overview:

Market Capitalization, $K 2,138,293
Enterprise Value, $K 1,929,103
Shares Outstanding, K 69,799
Annual Sales, $ 0 K
Annual Net Income, $ -151,760 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -72,710 K
EBIT, $ -269,260 K
EBITDA, $ -278,340 K
60-Month Beta -0.26
% of Insider Shareholders 7.94%
Float, K 64,257
% Float 92.06%
Short Volume Ratio 0.27

Growth:

1-Year Return 94.15%
3-Year Return 47.66%
5-Year Return 58.46%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.05 on 11/08/24
Next Earnings Date 11/11/24
Earnings Per Share ttm -3.75
EPS Growth vs. Prev Qtr -29.63%
EPS Growth vs. Prev Year -47.89%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

AKRO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -32.46%
Return-on-Assets % -29.83%
Profit Margin % 0.00%
Debt/Equity 0.05
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.92
Book Value/Share 10.63
Interest Coverage -3.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar